Silexion Therapeutics Corp
SLXNWNasdaq
$0.05
↑ +98.8%Jul 17 close · end-of-day
Price
1Y↑ +24.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$160,549.79
Enterprise Value
-$2.3M
P/E
0.0
P/S
—
P/B
0.6
EV/EBITDA
—
PEG
—
FCF Yield
-7483.7%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$12.9M
Free Cash Flow (TTM)
-$12.0M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-4436.4%
ROIC
—
Debt / Equity
—
Net Cash
$2.4M
Return 1Y
+25.5%
Company profile
Management & directors
- Hadar IlanChairman and CEO
- Horenshtein Hadar MiritCFO and Secretary
- Shirvan MitchellCSO and CDO
Roles derived from SEC Form 4 filings.
Earnings
SLXNW Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS$0.85↓ -77.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | — | — | — |
| Gross profit | — | — | — |
| Operating income | -$4.7M | -$12.6M | -$11.6M |
| Net income | -$5.1M | -$16.5M | -$11.9M |
| Diluted EPS | $44.23 | $394.94 | $8.96 |
| Operating cash flow | -$4.5M | -$8.4M | -$10.8M |
| Free cash flow | -$4.5M | -$8.4M | -$10.8M |
| Gross margin | — | — | — |
| Operating margin | — | — | — |
| Net margin | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$1.4M | -$8.0M | -$1.9M | -$1.6M | -$2.3M | -$3.3M | -$4.4M | -$2.7M |
| Net income | -$1.5M | -$11.9M | -$1.7M | -$1.7M | -$2.5M | -$3.3M | -$4.4M | -$2.7M |
| Diluted EPS | $197.80 | $274.25 | -$89.40 | $3.84 | $4.32 | $2.88 | -$2.08 | $0.85 |
| Operating cash flow | -$1.1M | -$2.7M | -$2.9M | -$2.5M | -$2.5M | -$2.8M | -$3.0M | -$3.6M |
| Free cash flow | -$1.1M | -$2.7M | -$2.9M | -$2.5M | -$2.5M | -$2.8M | -$3.0M | -$3.6M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Coming soonHeadlines for SLXNW will appear here once the news feed is connected.
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-04 | Shirvan Mitchell· CSO and CDO | Award | 6,000 | $0.00 | $0.00 | filing |
| 2026-06-04 | Horenshtein Hadar Mirit· CFO and Secretary | Award | 7,500 | $0.00 | $0.00 | filing |
| 2026-06-04 | Hadar Ilan· Chairman and CEO | Award | 10,000 | $0.00 | $0.00 | filing |
| 2026-03-26 | Shirvan Mitchell· CSO and CDO | Sale | 22,818 | $1.36 | $31,032.48 | filing |
| 2026-02-20 | Noy Shlomo | Award | 9,091 | $0.00 | $0.00 | filing |
| 2026-02-20 | Alon Ruth | Award | 9,091 | $0.00 | $0.00 | filing |
| 2026-02-20 | Shirvan Mitchell· CSO and CDO | Award | 49,726 | $0.00 | $0.00 | filing |
| 2026-02-20 | Horenshtein Hadar Mirit· CFO and Secretary | Award | 49,726 | $0.00 | $0.00 | filing |
| 2026-02-20 | Hadar Ilan· Chairman and CEO | Award | 64,350 | $0.00 | $0.00 | filing |
| 2026-02-20 | Abramov Dror Yosef | Award | 9,091 | $0.00 | $0.00 | filing |
| 2026-02-20 | Peled Amnon | Award | 7,576 | $0.00 | $0.00 | filing |
| 2026-02-20 | Lushi Avner | Award | 9,091 | $0.00 | $0.00 | filing |
| 2025-09-15 | Levin Ilan | Award | 450,000 | $4.00 | $1.8M | filing |
| 2025-08-07 | Levin Ilan | J | 5,550 | $0.00 | $0.00 | filing |
Latest 14 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.